Tepezza (teprotumumab) is the only FDA-approved medication for thyroid eye disease (TED), which is associated with Graves’ disease. Tepezza received FDA approval in January 2020.
Graves’ disease is an autoimmune disorder caused by the overproduction of thyroid hormones.
People with TED often experience bulging eyes, double vision, and eye pain.